Brokerages predict that NovaBay Pharmaceuticals, Inc. (NASDAQ:NBY) will report sales of $4.73 million for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for NovaBay Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $3.96 million and the highest estimate coming in at $5.50 million. NovaBay Pharmaceuticals reported sales of $6.32 million in the same quarter last year, which would suggest a negative year-over-year growth rate of 25.2%. The business is scheduled to issue its next earnings report on Tuesday, March 19th.
According to Zacks, analysts expect that NovaBay Pharmaceuticals will report full year sales of $0.00 for the current fiscal year. For the next fiscal year, analysts anticipate that the firm will report sales of $16.30 million. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that follow NovaBay Pharmaceuticals.
NovaBay Pharmaceuticals (NASDAQ:NBY) last announced its earnings results on Wednesday, November 14th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.02). The firm had revenue of $3.14 million during the quarter, compared to analysts’ expectations of $4.09 million.
About NovaBay Pharmaceuticals
NovaBay Pharmaceuticals, Inc, a pharmaceutical company, develops, manufactures, and markets anti-infective products for the eye care market in the United States. Its commercial products include the Neutrox family of products, Avenova for the eye care market; Aganocide compounds patented synthetic molecules with a range of spectrum of uses against bacteria, viruses, and fungi; Auriclosene Irrigation Solution for urology; CelleRx for the dermatology market; intelli-Case, a device for soft and rigid gas permeable contact lenses; and NeutroPhase for wound care.
Recommended Story: What is a stock buyback?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for NovaBay Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.